MyFinsight
Home
Blog
About
Contact
Proceeds from issuance of
convertible notes
$700,000K
Proceeds from issuance of
common...
$130,000K
Accounts receivable
-$203,185K
Proceeds from issuance of
warrants
$99,998K
Proceeds from issuance of
common stock-At The...
$48,156K
Proceeds from the
exercises of stock options
$5,048K
Stock-based compensation
$16,670K
Non-cash interest
expense on credit...
$14,357K
Non-cash interest
expense on liability...
$8,832K
Loss on equity method
investment
-$6,719K
Depreciation and
amortization
$6,368K
Prepaid expenses and
other current assets
-$4,769K
Amortization of convertible
notes issuance costs
$657K
Non-cash transfer of
property and equipment to...
$555K
Other
-$385K
Net cash provided by
financing activities
$795,717K
Net cash provided by
operating activities
$84,442K
Canceled cashflow
$187,485K
Canceled cashflow
$178,506K
Net (decrease)
increase in cash, cash...
-$14,123K
Canceled cashflow
$880,159K
Proceeds from maturities
of...
$124,518K
Proceeds from sales of
available-for-sale securities
$23,748K
Purchase of capped calls
$47,880K
something is missing
-$46,832K
Dividends paid by variable
interest entity to...
$41,514K
Payments of debt issuance
costs
$18,716K
Repayments of credit
facility
$17,826K
Payments of issuance
costs of common...
$13,393K
Payments of issuance
costs of common...
$1,324K
Net (loss) income
-$137,570K
Gain on vie's sale of
ipr&d assets
$19,000K
Accrued expenses
-$8,635K
Deferred revenue
-$8,599K
Accounts payable
-$2,190K
Accretion of
available-for-sale securities...
$1,300K
Operating lease, net
-$1,212K
Net cash used in
investing activities
-$894,282K
Canceled cashflow
$148,266K
Purchases of
available-for-sale securities
$1,061,577K
Back
Back
Cash Flow
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
source: myfinsight.com